United Non Current Assets Total from 2010 to 2024

UTHR Stock  USD 237.00  2.53  1.08%   
United Therapeutics Non Current Assets Total yearly trend continues to be relatively stable with very little volatility. Non Current Assets Total are likely to grow to about 3.8 B this year. Non Current Assets Total is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. View All Fundamentals
 
Non Current Assets Total  
First Reported
1999-03-31
Previous Quarter
3.6 B
Current Value
3.6 B
Quarterly Volatility
969 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check United Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among United main balance sheet or income statement drivers, such as Depreciation And Amortization of 55.9 M, Total Revenue of 2.4 B or Gross Profit of 2.2 B, as well as many exotic indicators such as Price To Sales Ratio of 4.2, Dividend Yield of 0.0089 or PTB Ratio of 1.63. United financial statements analysis is a perfect complement when working with United Therapeutics Valuation or Volatility modules.
  
This module can also supplement United Therapeutics' financial leverage analysis and stock options assessment as well as various United Therapeutics Technical models . Check out the analysis of United Therapeutics Correlation against competitors.
To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.

Latest United Therapeutics' Non Current Assets Total Growth Pattern

Below is the plot of the Non Current Assets Total of United Therapeutics over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. United Therapeutics' Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in United Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Non Current Assets Total10 Years Trend
Slightly volatile
   Non Current Assets Total   
       Timeline  

United Non Current Assets Total Regression Statistics

Arithmetic Mean1,753,201,733
Geometric Mean1,042,420,786
Coefficient Of Variation63.17
Mean Deviation919,998,613
Median1,431,500,000
Standard Deviation1,107,521,489
Sample Variance1226603.8T
Range3.8B
R-Value0.94
Mean Square Error147736.8T
R-Squared0.89
Slope233,390,200
Total Sum of Squares17172453.9T

United Non Current Assets Total History

20243.8 B
20233.6 B
20222.7 B
20212.8 B
20202.4 B
2019B
20181.6 B

About United Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include United Therapeutics income statement, its balance sheet, and the statement of cash flows. United Therapeutics investors use historical funamental indicators, such as United Therapeutics's Non Current Assets Total, to determine how well the company is positioned to perform in the future. Although United Therapeutics investors may use each financial statement separately, they are all related. The changes in United Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on United Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on United Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in United Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Current Assets Total3.6 B3.8 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether United Therapeutics is a strong investment it is important to analyze United Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact United Therapeutics' future performance. For an informed investment choice regarding United Stock, refer to the following important reports:
Check out the analysis of United Therapeutics Correlation against competitors.
To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.
Note that the United Therapeutics information on this page should be used as a complementary analysis to other United Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for United Stock analysis

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Is United Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of United Therapeutics. If investors know United will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about United Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.626
Earnings Share
19.81
Revenue Per Share
49.733
Quarterly Revenue Growth
0.251
Return On Assets
0.1122
The market value of United Therapeutics is measured differently than its book value, which is the value of United that is recorded on the company's balance sheet. Investors also form their own opinion of United Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is United Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because United Therapeutics' market value can be influenced by many factors that don't directly affect United Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between United Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if United Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, United Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.